GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CPT · Jun 30, 2026

CAMDEN PROPERTY TRUST. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001628280-26-051327Reit
Operating-cash-flow growth0thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.operating_cash_flow

-8.27% · OPTIONAL · VALID

Debt100thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.gross_debt

$4.8B · CORE · VALID

Net-income growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.net_income

-76.71% · CORE · NOT_ENOUGH_HISTORY

Revenue growth25thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

18.91% · CORE · VALID

Cash and equivalents75thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.cash

$44.7M · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-0.07%
Current
-8.27%
Delta
-8.19%
Debt Increased
Previous
$4.3B
Current
$4.8B
Delta
$597.8M
Earnings Growth Decreased
Previous
9.34%
Current
-76.71%
Delta
-86.05%
Growth Increased
Previous
-13.83%
Current
18.91%
Delta
32.75%
Liquidity Increased
Previous
$40.7M
Current
$44.7M
Delta
$4.0M
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.